- Home
- BIVI vs ALUR Comparison
BIVI vs ALUR Comparison
Compare BIVI & ALUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- ALUR
- Stock Information
- Founded
- BIVI 2013
- ALUR 2009
- Country
- BIVI United States
- ALUR United States
- Employees
- BIVI N/A
- ALUR N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- ALUR
- Sector
- BIVI Health Care
- ALUR
- Exchange
- BIVI Nasdaq
- ALUR Nasdaq
- Market Cap
- BIVI 18.6M
- ALUR 18.0M
- IPO Year
- BIVI N/A
- ALUR N/A
- Fundamental
- Price
- BIVI $0.97
- ALUR $2.57
- Analyst Decision
- BIVI
- ALUR Strong Buy
- Analyst Count
- BIVI 0
- ALUR 3
- Target Price
- BIVI N/A
- ALUR $22.83
- AVG Volume (30 Days)
- BIVI 210.2K
- ALUR 59.5K
- Earning Date
- BIVI 05-12-2025
- ALUR 08-12-2025
- Dividend Yield
- BIVI N/A
- ALUR N/A
- EPS Growth
- BIVI N/A
- ALUR N/A
- EPS
- BIVI N/A
- ALUR N/A
- Revenue
- BIVI N/A
- ALUR $28,304,000.00
- Revenue This Year
- BIVI N/A
- ALUR N/A
- Revenue Next Year
- BIVI N/A
- ALUR $49.37
- P/E Ratio
- BIVI N/A
- ALUR N/A
- Revenue Growth
- BIVI N/A
- ALUR N/A
- 52 Week Low
- BIVI $0.62
- ALUR $2.15
- 52 Week High
- BIVI $7.50
- ALUR $33.75
- Technical
- Relative Strength Index (RSI)
- BIVI 42.25
- ALUR 47.97
- Support Level
- BIVI $0.88
- ALUR $2.40
- Resistance Level
- BIVI $1.03
- ALUR $2.59
- Average True Range (ATR)
- BIVI 0.07
- ALUR 0.13
- MACD
- BIVI -0.02
- ALUR 0.01
- Stochastic Oscillator
- BIVI 23.97
- ALUR 58.33
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About ALUR Allurion Technologies Inc.
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.